Key terms

About CDXS

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CDXS news

Mar 01 11:04am ET Biotech Alert: Searches spiking for these stocks today Mar 01 7:48am ET Piper Sandler Sticks to Their Buy Rating for Codexis (CDXS) Mar 01 1:00am ET A New Cause for Concern: Codexis Adds a New Corporate Activity and Growth Risk Feb 29 9:55am ET Codexis upgraded to Buy at Benchmark after Q4 revenue and 2024 guidance Feb 29 9:34am ET Codexis upgraded to Buy from Hold at Benchmark Feb 29 8:19am ET Stifel Nicolaus Keeps Their Buy Rating on Codexis (CDXS) Feb 28 10:20pm ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Butterfly Network (BFLY) and Codexis (CDXS) Feb 26 4:19pm ET Codexis, Roche in licensing deal for newly engineered double-sranded DNA Ligase Feb 26 9:06am ET Craig-Hallum Gives a Buy Rating to Codexis (CDXS) Feb 20 8:17am ET Codexis appoints Damha, Lalonde to strategic advisory board Feb 13 4:42pm ET Codexis enters $40M loan facility agreement with Innovatus Feb 13 4:35pm ET Codexis Secures Strategic Financing to Support Growth Initiatives Feb 02 8:50am ET Analysts Offer Insights on Healthcare Companies: Codexis (CDXS) and Phathom Pharmaceuticals (PHAT) Jan 22 3:50pm ET Analysts Offer Insights on Healthcare Companies: Codexis (CDXS), Leap Therapeutics (LPTX) and Sutro Biopharma (STRO) Jan 22 1:12pm ET Piper Sandler Keeps Their Buy Rating on Codexis (CDXS) Jan 10 7:32am ET Codexis price target raised to $3 from $2 at TD Cowen Jan 09 12:05pm ET Codexis: Balancing Potential and Risks with a Hold Rating Amidst Market Challenges Dec 28 7:40am ET Analysts Are Bullish on These Healthcare Stocks: Globus Medical (GMED), DocGo (DCGO) Dec 27 8:35am ET Codexis enters into purchase agreement with Nestle Health Science for CDX-7108 Dec 27 8:34am ET Codexis enters into pruchase agreement with Nestle Health Science for CDX-7108 Dec 14 8:46am ET Craig-Hallum Keeps Their Buy Rating on Codexis (CDXS) Dec 13 4:15pm ET Codexis and Aldevron in licensing pact for Codex HiCap RNA Polymerase Dec 11 8:50am ET Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Codexis (CDXS) and NeuroOne Medical Technologies (NMTC) Dec 11 7:27am ET Codexis hosts KOL event on growth of RNAi therapeutics as a modality Dec 06 9:20am ET Analysts Offer Insights on Healthcare Companies: REPRO-MED Systems (KRMD) and Codexis (CDXS)

No recent news articles are available for CDXS

No recent press releases are available for CDXS

CDXS Financials

1-year income & revenue

Key terms

CDXS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CDXS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms